Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 267Triple Negative Breast Neoplasms 18Neoplasms 9Lymphedema 9Motor Activity 8Breast Cancer Lymphedema 8Breast Cancer Female 8Pathologic Complete Response 6Neoplasm Metastasis 6Colorectal Neoplasms 6Colonic Neoplasms 6Pain 5Fatigue 5Stomach Neoplasms 4Pain, Postoperative 4Recurrence 3Radiodermatitis 3Hereditary Breast and Ovarian Cancer Syndrome 3Endometrial Neoplasms 3Drug-Related Side Effects and Adverse Reactions 3Breast Diseases 3Advanced Breast Cancer 3Treatment Adherence and Compliance 2Thyroid Neoplasms 2Seroma 2Radiation Injuries 2Ovarian Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2

Interventions

apatinib 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Advanced Triple Negative Breast Cancer × Breast × Clear all
NCT05019690 2024-09-19

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Fujian Cancer Hospital

Phase 1/2 Recruiting
29 enrolled
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡